In 2020, in Europe, there were
58,169 cervical cancer cases
and 25,989 deaths.

Incidence and mortality rates vary widely across
Europe, with age-standardized incidence rates
ranging from less than 5 cases per 100,000 women
to above 25 cases per 100,000 women and
age-standardised mortality rates from 1
death per 100,000 women to 10
deaths per 100,000 women.
HPV vaccination coverages vary
considerably across Europe
Cervical cancer can be prevented by the HPV
vaccination, however HPV vaccination coverages
vary considerably across Europe from less
than 5% to more than 90%.
18 European countries and 34
partner organisations working
together to increase HPV vaccination coverage
specially in regions with low coverage and to
optimize data collection to monitor HPV vaccination
coverage and the impact of vaccination.



In 2020, in Europe, there were
58,169 cervical cancer cases
and 25,989 deaths.

Incidence and mortality rates vary widely across
Europe, with age-standardized incidence rates
ranging from less than 5 cases per 100,000 women
to above 25 cases per 100,000 women and
age-standardised mortality rates from 1
death per 100,000 women to 10
deaths per 100,000 women.
HPV vaccination coverages vary
considerably across Europe
Cervical cancer can be prevented by the HPV
vaccination, however HPV vaccination coverages
vary considerably across Europe from less
than 5% to more than 90%.
18 European countries and 34
partner organisations working
together to increase HPV vaccination coverage
specially in regions with low coverage and to
optimize data collection to monitor HPV vaccination
coverage and the impact of vaccination.

About PERCH

PERCH Kick – OFF Meeting – December 2022 – Brussels

Project PERCH brings together 18 European countries and 34 partner organizations with the objective of contributing to the implementation of Europe’s Beating Cancer Plan. PERCH aligns with the World Health Organization’s (WHO) “90-70-90” strategy, aiming to achieve at least 90% HPV vaccination coverage among girls, and potentially boys, by the age of 15 years.

Project objectives are:

  • Improve capacities of Member States to plan and implement HPV vaccination campaigns by sharing knowledge and experience.
  • Improve data and monitoring system on HPV vaccination and HPV screening.
  • Improve knowledge and awareness on HPV-related disease and prevention in specific target groups (adolescent girls and boys).
  • Improve knowledge and abilities for healthcare professionals in HPV vaccine communication.

SOCIAL MEDIA

Newsletter subscrition

Subscribe to PERCH newsletter and get the latest updates from European Partnership to Contrast HPV

NEWS

Prevent Human Papillomavirus infections. The European Joint Action “PartnERship to Contrast HPV (PERCH)” and the training path remotely for health personnel – ISS News

  Human Papilloma infections prevention. The european Joint Action partnERschip to contrast HPV (PERCH) and e-lerning for the health professionals – Papillomavirus (HPV) infection is the most common sexually transmitted infection (in both sexes). Vaccines against HPV have been available since 2006 and although they have been progressively introduced in

Read More »
NEWS

Improving HPV vaccine communication training for healthcare professionals

Work Package 7 (WP) of the PERCH project is dedicated to improving the communication skills of healthcare professionals regarding the human papillomavirus (HPV) vaccine. By improving communication between healthcare professionals, children/adolescents and their parents, WP7 aims to increase confidence in the HPV vaccine. The first task was a comprehensive assessment

Read More »
EVENTS

PERCH WP2 meeting

The PERCH WP2 meeting produced valuable results On 24 and 25 April 2024, health and communication experts from the PERCH partner countries met in person in Ljubljana and via Zoom. The main purpose of the PERCH WP2 meeting was to facilitate discussions and collaboration between the participating countries on the

Read More »

Newsletter subscrition

Subscribe to PERCH newsletter and get the latest updates from European Partnership to Contrast HPV

Skip to content